Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. - Wikidata - awgldk - TriplyDB

Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

http://www.wikidata.org/entity/Q33991008

about

Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology Cancer stem cells and drug resistance: the potential of nanomedicine Lipid-Based Nanocarriers for RNA Delivery Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor Lipid-based vectors for siRNA delivery Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Recent advances in nonviral vectors for gene delivery.Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.Combination drug delivery approaches in metastatic breast cancer Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer Utilisation of nanoparticle technology in cancer chemoresistance.Delivery of intracellular-acting biologics in pro-apoptotic therapies.Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.Enhancing cell nucleus accumulation and DNA cleavage activity of anti-cancer drug via graphene quantum dots.Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery.Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity.Multifunctional Nanographene Oxide for Targeted Gene-Mediated Thermochemotherapy of Drug-resistant Tumour.Strategies for tumor-directed delivery of siRNA.Antibody-targeted nanoparticles for cancer therapy.Recent advances of siRNA delivery by nanoparticles.Nanocarriers: a tool to overcome biological barriers in siRNA delivery.Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.A daunting task: manipulating leukocyte function with RNAi.Recent advances in delivery of drug-nucleic acid combinations for cancer treatment Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Nanomaterials for targeted drug delivery to cancer stem cells.Nanodrug delivery in reversing multidrug resistance in cancer cells.A Natural Bacterium-Produced Membrane-Bound Nanocarrier for Drug Combination Therapy.

P2860

Q26849264-C5B1D1EA-9FA5-4EAA-8CC7-B60A9C24CF3D Q26998993-587C219F-4A64-420C-BB68-096F9A913751 Q28080706-19C10478-D19D-4BE8-A902-022B46893FEA Q28535429-CC253B95-F2A9-491E-B56B-3814D5AEAC8D Q28541628-0BCF25C1-4808-41A1-AED7-5A5979AAFF9E Q28543911-7699A51F-93DA-41A1-83CF-BA7FFBDD5326 Q28828356-EF76B3FE-717D-425F-B7FC-FCBB50CBF69B Q33735020-928247D0-AD94-428D-908C-27867FA22147 Q33935474-E4DD3F25-695A-4663-93B6-1C9DE072FBC9 Q33935498-585A8E58-D07C-4103-8E7B-D8AC2CDE54A0 Q34361211-6248B88B-9E81-4C9C-8F08-B7ABAF56B82A Q34622662-C4B176B6-39C2-458A-91E8-F34D533C9C58 Q35618915-E28862D7-172E-4FF9-8B07-2A0F1791E899 Q35751958-8508F038-A63D-45D2-90D2-53A7162B8644 Q35903717-84F15A2B-EB6B-4758-9018-B328ACD85E6C Q35924301-C5B380D3-F596-4626-A539-87C923E831BD Q35955198-4FD93ACF-D280-40C9-B1BD-6D1074E143F0 Q36144913-A10728AF-EA23-4E0D-9993-6E6DAA5AA6E4 Q36421258-9B0F9E05-3FC6-4B86-A379-A3B6691D1318 Q36588920-BDA0E7DC-4FD9-40AB-811B-AC71C08ADBFB Q36749553-3D4E6814-613E-4518-9473-CE43C87BA2DA Q37031597-8A186733-8C98-4DB2-9F66-3FBC13CC5E0B Q37214403-FE938581-3758-444C-B75F-C8723F9D1316 Q37251480-2E20F921-9FF9-4D7C-BC97-1870B0EB8B35 Q37254863-09F51CFB-0770-479C-8B37-ABFB197FD31C Q37495209-E8676693-94AC-4EDB-8423-0B0B57697BD9 Q37685914-9038C5B7-8ACE-4FC3-B0B1-F5FB81F19875 Q37840092-AF9952D3-6910-4882-ACC4-19EF0E36B8BA Q37851969-BA4AD9BA-78E6-4A4A-9813-97601DF7FDAF Q37854061-A51BCAF8-FD68-40A3-B406-948DB8A26E99 Q37891091-ACF0D032-EEE1-46E9-8D8C-34CBFEFE3827 Q37938830-99E3D8C4-103F-43D9-96D4-7A04246BBA9A Q38074442-27C93521-FB90-46FC-94FF-F8E68A7135EA Q38095502-8DE39EEE-3972-46AC-8085-6BAD5D6A1990 Q38102522-99A39E5D-9BE7-4B6B-AB9D-A01E3F7554C4 Q38150118-9885A1BF-E74E-4D7C-8B45-25FE18C64CED Q38183852-DF79D9C2-7313-472C-99F4-A7BF88732878 Q38201740-5F3205FA-2706-4386-AF12-9B6D4E81FB88 Q38234908-7DA63212-415E-43CD-95C3-CBBFB97735E0 Q38647298-579230E8-CD31-4922-9BEC-FDF1C3766C98

P2860

Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

http://www.wikidata.org/entity/Q33991008

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Multifunctional nanoparticles ...... ome drug resistance in cancer.

@ast

Multifunctional nanoparticles ...... ome drug resistance in cancer.

@en

type

label

Multifunctional nanoparticles ...... ome drug resistance in cancer.

@ast

Multifunctional nanoparticles ...... ome drug resistance in cancer.

@en

prefLabel

Multifunctional nanoparticles ...... ome drug resistance in cancer.

@ast

Multifunctional nanoparticles ...... ome drug resistance in cancer.

@en

P1433

Q33991008-84945D03-D836-4646-BE24-64EFA7B3E092

P1476

Q33991008-7BC42DA1-81A5-4A31-B3A7-5AD170344BEC

P2093

Q33991008-931ED684-C47D-470B-8E10-189CEFD340DD

Q33991008-B068175E-B97E-4C54-8C0C-03B5BE996A47

Q33991008-FEDBA24C-30B4-426E-AA88-36F34D4E9903

P2860

Q33991008-1E59D1FC-1783-49BC-A830-91C54301E551

Q33991008-22893E89-7750-41C7-B0B4-2DD6468FB2A2

Q33991008-35674441-540F-4B28-AAA2-21BB18C02CA0

Q33991008-370B8020-1897-4050-8429-50B7C8C1094D

Q33991008-37FA2379-2125-4612-AD19-F2DF5FF290EA

Q33991008-38493364-7E40-49D6-9BB1-A651A2056601

Q33991008-397A0081-A30B-4EE9-B3DB-7CB2320E9EEF

Q33991008-57643F6C-089D-4AC5-BDA9-C29098C18AAF

Q33991008-64BF32EF-752C-4EC0-A53A-89337EEBCB39

Q33991008-691EF5A5-18E4-412C-9D94-436BA8C2D39A

P304

Q33991008-77CDE324-9280-44AD-BFEF-FCFB0A128FE5

P31

Q33991008-710A7616-7A40-4428-9E44-B6E90DB3461B

P356

Q33991008-5255C1C6-28C7-423B-B334-8A9E42403107

P407

Q33991008-60800CBA-DA80-48F4-B7CA-7BCC609CEF2D

P433

Q33991008-F696CF67-B044-4F14-BBEB-CC309D5D4216

P478

Q33991008-2D65A4E2-C0E5-4151-95F7-E23B76AB3324

P50

Q33991008-AAAF946A-4BDE-43ED-A1F9-EFA79FC6C4CF

P577

Q33991008-B0D1D0B6-9087-42AE-A8B3-EDE8BCF8161B

P698

Q33991008-01DDE31E-9765-4743-B9F6-DDC3FA1584D3

P921

Q33991008-8B3DEE3A-763F-40FE-8D2D-D5EE8FD98595

P932

Q33991008-5AF5F316-E3F1-49C4-8592-ED295CE35640

P356

JBC.M110.125906

P1433

Journal of Biological Chemistry

P1476

Multifunctional nanoparticles ...... come drug resistance in cancer

@en

P2093

Jun Li

http://www.w3.org/2001/XMLSchema#string

Leaf Huang

http://www.w3.org/2001/XMLSchema#string

Surendar Reddy Bathula

http://www.w3.org/2001/XMLSchema#string

P2860

Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression under K-selection after MYC and HRAS oncogene activation

Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis

Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.

Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan

A role for guanidino compounds in the brain.

siRNA-based approaches in cancer therapy.

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.

Advances in the development of siRNA-based therapeutics for cancer.

Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.

Biochemistry and neurotoxicology of guanidino compounds. History and recent advances.

P304

22639-22650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.125906

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

285

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20460382

http://www.w3.org/2001/XMLSchema#string

P921

P932

2903346

http://www.w3.org/2001/XMLSchema#string